Arena Pharmaceuticals Inc
F:RN3N
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
A
|
Arena Pharmaceuticals Inc
F:RN3N
|
5.6B EUR |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.3B USD |
Loading...
|
Market Distribution
| Min | -1 929 242.2% |
| 30th Percentile | 0.1% |
| Median | 6.3% |
| 70th Percentile | 13.7% |
| Max | 1 135 400% |
Other Profitability Ratios
Arena Pharmaceuticals Inc
Glance View
Arena Pharmaceuticals Inc., once a promising player in the biotechnology space, carved out a niche in developing novel therapies aimed at addressing unmet needs in various therapeutic areas. The company focused heavily on its proprietary drug discovery and development platform, which centered around designing and creating small molecules to activate specific receptor subtypes. This mechanism allows them to produce targeted treatments with fewer side effects, thus appealing to a market in search of more specialized therapies. At the core of Arena's portfolio was its work in the fields of cardiology, gastroenterology, and dermatology, where the company ambitiously advanced its drug candidates through meticulous research and clinical trials, hoping to bring these innovations to patients worldwide. Arena's revenue-generating strategy primarily revolved around developing these new pharmaceuticals to the point where they became attractive for partnerships or acquisitions. The company often engaged in strategic collaborations with larger pharmaceutical players, licensing its products under development, which provided crucial funding for ongoing research while retaining some rights to future revenues. This model allowed Arena to leverage the market reach and financial muscle of its partners without bearing the full brunt of commercializing a drug. This symbiotic relationship was critical for Arena’s financial stability, offering a combination of upfront payments, milestone achievements, and eventual royalties. In a constantly evolving and competitive biopharmaceutical landscape, Arena’s approach aimed to balance innovative breakthroughs with practical business acumen.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
Over the last 3 years, Arena Pharmaceuticals Inc’s Net Margin has decreased from -187.4% to -1 325 181.2%. During this period, it reached a low of -1 298 056.8% on Jan 31, 2022 and a high of 85.6% on Mar 31, 2019.